Psychiatry and Neurology, Neurology · Knoxville, TN
NPI
1083681183
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
140 Market Place Blvd Bldg E
Knoxville, TN, 37922
Phone (865) 531-9430
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
3,415 services
Medicare patients, 2024
124
Average age 65
Drug cost, 2024
$2.8M
5,573 prescriptions
Company payments, 2025
$1,753
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samir Al-Kabbani was code 99213 (office e&m - established), 91 times for 62 patients. In total Samir Al-Kabbani billed 3,415 services in 17 codes, and Medicare paid $39K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 91 | 62 | $56.49 | $5,141 |
| 99212 Office E&M - Established | Office | 66 | 51 | $34.01 | $2,244 |
| 95886 Electrical Nerve Conductivity | Office | 43 | 13 | $66.77 | $2,871 |
| 99203 Office E&M - New | Office | 31 | 31 | $75.21 | $2,332 |
| 95816 Neurologic | Office | 22 | 22 | $277.65 | $6,108 |
By year: 2022 $62K for 5,627 services; 2023 $57K for 6,620 services; 2024 $39K for 3,415 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samir Al-Kabbani prescribed most often to Medicare patients was Levetiracetam, with 627 prescriptions and refills. In total Samir Al-Kabbani wrote 5,573 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 627 | 1,031 | 128 | $18K |
| Gabapentin Generic | 576 | 632 | 95 | $9,297 |
| Lacosamide Generic | 488 | 524 | 78 | $49K |
| Lamotrigine Generic | 300 | 401 | 54 | $6,493 |
| Cyclobenzaprine Hcl Generic | 195 | 235 | 43 | $1,994 |
| Tizanidine Hcl Generic | 193 | 247 | 34 | $3,394 |
| Topiramate Generic | 180 | 278 | 32 | $1,980 |
| Aptiom Eslicarbazepine Acetate | 175 | 175 | 24 | $351K |
| Pregabalin Generic | 155 | 171 | 25 | $3,627 |
| Clonazepam Generic | 124 | 124 | 27 | $790 |
| Fycompa Perampanel | 112 | 120 | 13 | $147K |
| Phenobarbital Generic | 106 | 124 | 19 | $1,608 |
| Briviact Brivaracetam | 94 | 94 | 17 | $140K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 93 | 139 | 17 | $1,272 |
| Carbamazepine Generic | 88 | 128 | 17 | $4,035 |
Brand drugs: 1,092 claims; generic drugs: 4,375 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samir Al-Kabbani $1,753 ($1,753 in general payments such as food, travel and fees) from 16 companies. The largest payer was Neurelis, Inc. with $391.
| Company | Payments | Amount |
|---|---|---|
| Neurelis, Inc. | 12 | $391 |
| UCB, Inc. UCB.BR | 15 | $325 |
| Scilex Pharmaceuticals Inc. | 11 | $180 |
| SK Life Science, Inc. | 10 | $153 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $139 |
| Abbvie Inc. ABBV | 6 | $108 |
| Genentech USA, Inc. ROG.SW | 5 | $93.18 |
| Neurocrine BioSciences, Inc. NBIX | 5 | $92.01 |
| Cycle Pharmaceuticals Inc | 4 | $69.47 |
| Amgen Inc. AMGN | 2 | $42.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.